Bactericidal activity of increasing daily and weekly doses of moxifloxacin in murine tuberculosis

Antimicrobial Agents and Chemotherapy

Volumn 46, Issue 6, 2002, Pages 1875-1879

  Yoshimatsu, Tetsuyuki ^a   Nuermberger, Eric ^a   Tyagi, Sandeep ^a   Chaisson, Richard ^a   Bishai, William ^a   Grosset, Jacques ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMYCOBACTERIAL AGENT; BACTERICIDE; ISONIAZID; MOXIFLOXACIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; BACTERICIDAL ACTIVITY; COLONY FORMING UNIT; CONTROLLED STUDY; DISEASE COURSE; DOSE RESPONSE; DRUG EFFECT; DRUG HALF LIFE; DRUG POTENCY; FEMALE; MOUSE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; TUBERCULOSIS; WEIGHT GAIN;

ANIMALS; ANTI-INFECTIVE AGENTS; AZA COMPOUNDS; COLONY COUNT, MICROBIAL; FEMALE; FLUOROQUINOLONES; LUNG; MICE; MICE, INBRED BALB C; MYCOBACTERIUM TUBERCULOSIS; QUINOLINES; SPLEEN; SURVIVAL ANALYSIS; TUBERCULOSIS;

EID: 0036090655     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.46.6.1875-1879.2002     Document Type: Article

References (16)

1. Absolute bioavailability of moxifloxacin
2. Serial counts of Mycobacterium tuberculosis in sputum as surrogate markers of the sterilizing activity of rifampicin and pyrazinamide in treating pulmonary tuberculosis
3. Statistics in practice. Comparing the means of several groups
4. In vitro and in vivo activities of moxifloxacin and clinafloxacin against Mycobacterium tuberculosis
5. Effectiveness of once-weekly rifapentine and moxifloxacin regimens against Mycobacterium tuberculosis in mice
6. Comparative pharmacokinetics of ciprofloxacin, gatifloxacin, grepafloxacin, levofloxacin, trovafloxacin, and moxifloxacin after single oral administration in healthy volunteers
7. Moxifloxacin (BAY12-8039), a new 8-methoxyquinolone, is active in a mouse model of tuberculosis
8. The need for new drugs against tuberculosis. Obstacles, opportunities, and next steps
9. New tuberculosis drug development. How can we do better?
10. Using therapeutic drug monitoring to dose the anti-mycobacterial drugs
11. Pharmacokinetics, safety, and tolerability of ascending single doses of moxifloxacin, a new 8-methoxy quinolone, administered to healthy subjects
12. Pharmacokinetics and elimination of moxifloxacin after oral and intravenous administration in man
13. Pharmacokinetics of a once-daily oral dose of moxifloxacin (Bay 12-8039), a new enantiomerically pure 8-methoxy quinolone
14. Preclinical safety evaluation of moxifloxacin, a novel fluoroquinolone
15. Pharmacokinetics and inflammatory-fluid penetration of moxifloxacin following oral or intravenous administration
16. In vitro activity of BAY 12-8039, a new fluoroquinolone